Coming Soon – April 2019 Premium-priced therapies in ovarian cancer,...
Coming Soon – April 2019 Premium-priced therapies in ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca), Rubraca (Clovis...
Coming soon – April 2019 MARKET OUTLOOK Clinical pathways, which...
Coming soon – April 2019 MARKET OUTLOOK Clinical pathways, which establish optimal treatment protocols for specific patient populations based on the...
Market Outlook Malignant melanoma is the most aggressive and life-...
Market Outlook Malignant melanoma is the most aggressive and life-threatening skin cancer, the incidence of which continues to rise despite recent therapeutic advances.......
Although angiogenesis inhibitors are a mainstay in the treatment of renal cell...
Although angiogenesis inhibitors are a mainstay in the treatment of renal cell carcinoma, Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibit...
Market Outlook Characterized by high incidence and long treatment durations...
Market Outlook Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. ...
Market Outlook Squamous cell carcinoma of the head and neck (SCCHN) is an...
Market Outlook Squamous cell carcinoma of the head and neck (SCCHN) is an anatomically and biologically......
Market Outlook NSCLC has one of the most dynamic drug development pipelines...
Market Outlook NSCLC has one of the most dynamic drug development pipelines in oncology with multiple targeted and biomar......
Market Outlook Immune checkpoint inhibitors are revolutionizing the...
Market Outlook Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 201......
The high number of premium-priced NSCLC therapies and the large number of...
The high number of premium-priced NSCLC therapies and the large number of NSCLC patients result in......
Market Outlook Therapeutic options for gastroesophageal cancer are limited;...
Market Outlook Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and ...
Market Outlook Prostate cancer is the most common cancer among men in...
Market Outlook Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routin...
The ovarian cancer treatment algorithm is rapidly evolving. For decades,...
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy has been the standard of care for ovarian cancer; however, treatment is changing to a targeted approach with......
Market Outlook Hepatocellular carcinoma (HCC) is a primary malignancy of the...
Market Outlook Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, with the majority of cases arising from......
Market Outlook Biomarker-driven prescribing continues to play an...
Market Outlook Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-......
Colorectal cancer is the third-most-common cancer globally and is associated...
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for metastatic colorectal cancer is dominated by ch...
DRG Epidemiology's coverage of hepatocellular carcinoma comprises...
DRG Epidemiology's coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalen......
Market Outlook The treatment armamentarium of mCRPC has significantly...
Market Outlook The treatment armamentarium of mCRPC has significantly evolved with the addit...
MARKET OUTLOOK QUESTIONS ANSWERED What are the treatment drivers and...
MARKET OUTLOOK QUESTIONS ANSWERED What are the treatment drivers and goals for [[indication]]? What......
The genetic complexity and heterogeneity of gastric and GEJ adenocarcinoma...
The genetic complexity and heterogeneity of gastric and GEJ adenocarcinoma poses a significant challenge for the development of treatment strategies......
Market Outlook Despite the number of therapy options available, metastatic...
Market Outlook Despite the number of therapy options available, metastatic HR-positive/...
